Literature DB >> 11427284

Intranasal immunisation with influenza-ISCOM induces strong mucosal as well as systemic antibody and cytotoxic T-lymphocyte responses.

S Sjölander1, D Drane, R Davis, L Beezum, M Pearse, J Cox.   

Abstract

Intranasal administration of vaccines is preferred for induction of mucosal immune responses. In this study, mice were immunised intranasally and subcutaneously with influenza-immuno stimulating complexes (influenza-ISCOM). The intranasal dose was 15-times the subcutaneous dose. All mice dosed with influenza-ISCOMs survived challenge with live virus and comparable serum antibody and splenic cytotoxic T-lymphocyte responses were detected in both groups. Induction of mucosal IgA was significantly higher with intranasal immunisation and was comparable to responses induced with the heat labile enterotoxin of Escherichia coli as adjuvant. These findings demonstrate that intranasal administration of high dose influenza-ISCOM results in potent systemic and mucosal immune responses.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11427284     DOI: 10.1016/s0264-410x(01)00110-4

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  9 in total

Review 1.  Mucosal immunity: overcoming the barrier for induction of proximal responses.

Authors:  Brent S McKenzie; Jamie L Brady; Andrew M Lew
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

Review 2.  Veterinary vaccine nanotechnology: pulmonary and nasal delivery in livestock animals.

Authors:  Daniella Calderon-Nieva; Kalhari Bandara Goonewardene; Susantha Gomis; Marianna Foldvari
Journal:  Drug Deliv Transl Res       Date:  2017-08       Impact factor: 4.617

3.  Mutants of type II heat-labile enterotoxin LT-IIa with altered ganglioside-binding activities and diminished toxicity are potent mucosal adjuvants.

Authors:  Hesham F Nawar; Sergio Arce; Michael W Russell; Terry D Connell
Journal:  Infect Immun       Date:  2006-11-21       Impact factor: 3.441

4.  Evaluation of the sublingual route for administration of influenza H5N1 virosomes in combination with the bacterial second messenger c-di-GMP.

Authors:  Gabriel Kristian Pedersen; Thomas Ebensen; Ingrid Hjetland Gjeraker; Signe Svindland; Geir Bredholt; Carlos Alberto Guzmán; Rebecca Jane Cox
Journal:  PLoS One       Date:  2011-11-01       Impact factor: 3.240

5.  Matrix-M adjuvanted virosomal H5N1 vaccine confers protection against lethal viral challenge in a murine model.

Authors:  Gabriel Pedersen; Diane Major; Sarah Roseby; John Wood; Abdullah S Madhun; Rebecca J Cox
Journal:  Influenza Other Respir Viruses       Date:  2011-05-09       Impact factor: 4.380

Review 6.  Viral nanoparticles and virus-like particles: platforms for contemporary vaccine design.

Authors:  Emily M Plummer; Marianne Manchester
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2010-09-24

7.  Oral Bacteria Combined with an Intranasal Vaccine Protect from Influenza A Virus and SARS-CoV-2 Infection.

Authors:  Minami Nagai; Miyu Moriyama; Takeshi Ichinohe
Journal:  mBio       Date:  2021-08-17       Impact factor: 7.867

Review 8.  Nanotechnology in vaccine delivery.

Authors:  Laura J Peek; C Russell Middaugh; Cory Berkland
Journal:  Adv Drug Deliv Rev       Date:  2008-02-07       Impact factor: 15.470

9.  A TLR3 ligand that exhibits potent inhibition of influenza virus replication and has strong adjuvant activity has the potential for dual applications in an influenza pandemic.

Authors:  Yuk-Fai Lau; Lay-Hoon Tang; Eng-Eong Ooi
Journal:  Vaccine       Date:  2009-01-15       Impact factor: 3.641

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.